A 26-week double-blind randomised trial testing once-weekly semaglutide added to automated insulin delivery in 72 adults with type 1 diabetes and obesity. PICO summary and expert commentary.
Browsing: Type 1 Diabetes
A FOURIER subgroup analysis of 197 participants asks whether evolocumab cuts cardiovascular events in type 1 diabetes with established ASCVD. PICO summary and expert commentary.
In children aged 2-6 years with type 1 diabetes, the MiniMed 780G in auto mode improved time in range and HbA1c over manual mode with suspend-before-low, meeting non-inferiority with superiority. PICO summary and expert commentary.
A 13-week randomised trial found automated insulin delivery sharply lowered HbA1c in youth with type 1 diabetes but objectively reduced sleep efficiency and increased night-time wakefulness. PICO summary and expert commentary.
In 28 AID-naive adults with type 1 diabetes, a tubeless open-source hybrid loop (AndroidAPS) raised time in range to 75.6 percent versus 60.4 percent on sensor-augmented pump therapy without added hypoglycaemia. PICO summary and expert commentary.
A randomized crossover trial found the cardiac output response to 3-hydroxybutyrate was blunted by roughly 80% in type 1 diabetes, with no gain in systolic function and reduced ventricular work efficiency. PICO summary and expert commentary.
Two small crossover trials in adults with type 1 diabetes found neither protein source nor carbohydrate glycaemic index significantly altered postprandial glucose. PICO summary and expert commentary.
Two acute randomized crossover trials found that neither dietary protein source nor carbohydrate glycaemic index significantly altered postprandial glucose in adults with type 1 diabetes. PICO summary and expert commentary.
A pragmatic RCT testing whether brief telehealth problem-solving therapy (LISTEN) reduces diabetes distress in adults with type 1 and type 2 diabetes versus usual web-based resources. PICO summary and expert commentary.
The PARTNER study is a published trial protocol, not a results paper: it describes the rationale and design of a randomised crossover trial of dapagliflozin plus continuous ketone monitoring in type 1 diabetes, with no outcomes yet reported. PICO summary and expert commentary.